Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: A double-blind placebo-controlled cross-over trial.
Study design (if review, criteria of inclusion for studies)
double-blind placebo-controlled crossover-trial.
Participants
23 CF patients with chronic rhinosinusitis
Interventions
patients were randomised to inhale either dornase alfa or isotonic saline for 28 days with the Pari-Sinus and after 28 days (wash-out) crossed over to the alternative treatment.
Outcome measures
The primary outcome parameter was primary nasal symptom score in the disease-specific quality of life Sino-Nasal Outcome-Test-20 (SNOT-20: nasal obstruction/sneezing/runny nose/thick nasal discharge/reduced smelling).
Main results
Primary nasal symptoms improved significantly with dornase alfa compared with no treatment, while small improvements with isotonic saline did not reach significance. SNOT-20 overall scores improved significantly after dornase alfa compared with isotonic saline (p=0.017). Additionally, sinonasal dornase alfa but not isotonic saline significantly improved pulmonary function (FEF75-25: p=0.021).
Authors' conclusions
Vibrating sinonasal inhalation of dornase alfa reduces rhinosinusitis symptoms in CF.
Keywords: Bacterial Infections; Deoxyribonuclease; Infection; Inhalation OR nebulised; nebuliser; non pharmacological intervention - devices OR physiotherapy; pharmacological_intervention; Recombinant Proteins; Respiratory Tract Infections; Sinusitis; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Respiratory System Agents; Respiratory Tract Diseases; Dornase alpha; Pulmozyme; vibration;